TrialSite News researchers are providing a service unlike any other: much-awaited consumer information surrounding clinical trials that treat a range of diseases and conditions. In this summary, we are covering Pacific Hematology Oncology Associates, a clinical investigation site participating in the study of a new treatment method for metastatic castration resistant prostate cancer.
About Pacific Hematology Oncology Associates
According to their website, “Pacific Hematology Oncology Associates was founded by Drs. Robert Rodvien and Kathleen Grant in 1979 to be the premier hematology oncology practice at California Pacific Medical Center and in the city of San Francisco. Since then we have grown in size and scope, but have maintained our reputation for excellence by providing the most up to date care, with compassion and an unwaivering commitment to our patients.” Pacific Hematology Oncology Associates is a team of people committed to caring for people with blood and cancer disorders, and providing comprehensive and compassionate care.
Clovis Oncology, Inc. is sponsoring this study, officially titled “TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician’s Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency.” Founded in 2009, Clovis Oncology is a commercial stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets.
Clovis’ product development programs generally target specific subsets of cancer, and the Company seeks to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, Clovis has the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths. Clovis believes this approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy.
Study Details and Participation
The actual study start date was in June 2017 and it’s estimated completion date is in April 2022. The estimated enrollment is 400 participants. It is currently recruiting participants, depending on location. Pacific Hematology Oncology Associates , however, is still in the recruiting stage.
Key Principal Investigator
TrialSite News researchers believe Ari D. Baron, M.D. to be the Key Prinicipal Investigator at Pacific Hematology Oncology Associates., according to the following information on their website: “Dr. Baron serves as Chief of the Division of Hematology Oncology, and leads quality improvement for the medical center in our field. Among the many projects he has led, we have just released multilingual teaching videos on oncology care in Spanish, Chinese and Russian to improve our cross-cultural capacity to teach and care for our patients. In addition, Dr Baron is the Director of Clinical Oncology Research, and has been coauthored on many important studies including the trial that led to the FDA approval of Avastin in colon cancer, and Opdivo in bladder cancer. Clinical research continues to be his main focus.”
No significant FDA Warning Letters or Inspections appeared upon our initial inspection of Pacific Hematology Oncology Associates. You may, however, learn more about their online reputation on Yelp, Facebook or their Google Listing.
Call to Action: Transparency to patients is our foremost concern at TrialSite News, and we will continue to provide telling reviews of clinical investigation sites involved in the study of many new medical treatments. Sign up for our Daily Digest to receive future news on the clinical trial industry.